Spectro-dosemeter-based gamma dose rate network in Germany.

As a consequence of the Chernobyl accident in 1986 the Integrated Measurement and Information System (IMIS) was established (Weiss and Leeb, 1993) which includes on-line monitoring networks for the surveillance of radioactivity in Germany. Today, the German Federal Office for Radiation Protection (BfS) operates a gamma dose rate network with 1800 ambient dose equivalent rate H*(10) (ADER) stations almost equally distributed over the German territory. The ADER network integrates Geiger-Müller (GM) based detectors which, if low and high dose rate tubes are combined, are known to have excellent long-term stability and an extended dose rate range from environmental background level (20 nSv/h) up to several Sv/h. However, one main drawback is the lack of information about nuclides contributing to the observed dose rate. Therefore BfS has started to integrate LaBr3-based spectrometric detector systems (so-called spectro-dosemeters) in the existing ADER network. In this paper detector design, quality assurance and quality control (QA/QC) procedures are described as well as efforts required to characterize and operate monitoring networks based on spectrometric detectors.

Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation.

Local therapy of pancreatic cancer with microencapsulated CYP2B1-producing cells and ifosfamide showed an effect both on the primary tumor and on distant metastatases. This possibly represents a consequence of the activation of immune response. Other studies have demonstrated that local tumor irradiation leads to the activation of the intratumoral lymphocyte infiltration. The aim of our study was to investigate the efficacy of the combined therapy with low-dose irradiation, ifosfamide and CYP2B1-producing cells. Syngenic pancreatic cancer was induced in 38 Lewis-rats by subcutaneous inoculation of 1 x 10(6) (DSL6A) tumor cells. Microencapsulated CYP2B1-producing cells were injected peritumorally 10--12 weeks after tumor implantation. Animals were randomized to the following groups: 1) control (NaCl, 1 ml i.p.), 2) ifosfamide (50 mg/kg, i.p., (3x/week), 3) local irradiation with 5 Gy and 4) ifosfamide plus irradiation. The tumor growth was monitored for 3 weeks. The tumor infiltration with CD4+, CD8+, NK-cells, microvessel density and proliferation rates were investigated by immunohistochemistry. Cytokine plasma level for TNF-alpha were measured by ELISA. Seven of 9 animals in the group of combined therapy showed an objective response to the therapy. The therapy with ifosfamide or radiation alone showed 5 and 3 responders, respectively. The mean tumor volume was significantly reduced after combined ifosfamide plus radiation therapy in the first week, whereas monotherapy with ifosfamide or radiation significantly decreased tumor growth earliest after 2 and 3 weeks, respectively. The high plasma level of TNF-alpha in the control group was significantly reduced after combined ifosfamide/irradiation treatment. The lymphocyte infiltration and tumor proliferation were not significantly different between the groups. Microvascular density was significantly increased after ifosfamide and ifosfamide plus irradiation therapy. The combination of ifosfamide/CYP2B1-producing cells and irradiation showed an earlier therapeutical effect on the growth of rat pancreatic cancer than the irradiation or ifosfamide alone. There was no evidence of late activation of lymphocyte infiltration and PCNA-positive tumor cells.